“SINTX is the only FDA-registered producer of implantable silicon nitride, with a robust portfolio that includes monolithic ceramic implants, particulate-based coatings, microspheres and composite materials. These innovations are aimed at enhancing osseointegration and reducing bacterial colonization, key factors in improving implant longevity and patient safety.”
Link to their website shows the many applications of Silicon Nitride in many different fields:
“This sale represents an important milestone in our strategic realignment,” said Eric K. Olson, CEO of SINTX Technologies. “By divesting of these assets, we are fully committing our resources to the medical device market, where our expertise in advanced ceramics can have the greatest impact. This transaction not only enhances our financial flexibility but also supports our efforts to accelerate product development and commercialization efforts in healthcare.”
